Diadema Partners »

Sellas Life Sciences Group I shares owned by Diadema Partners

Quarter-by-quarter ownership of Sellas Life Sciences Group I (SLS) shares owned by Diadema Partners from 13F filings

Historical chart of Diadema Partners investment in Sellas Life Sciences Group I

Tip: Access up to 7 years of quarterly data

All positions including Sellas Life Sciences Group I held by Diadema Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sellas Life Sciences Group I by Diadema Partners

Quarter filed Position value Share count Share price at filing
2025-09-30 $644k 400k 1.61

More positions owned by Diadema Partners

Jazz Pharmaceuticals Shs Usd (JAZZ)
Soleno Therapeutics (SLNO)
Uniqure Nv SHS Put Option (QURE)
Regeneron Pharmaceuticals (REGN)
Viking Therapeutics (VKTX)
Bristol Myers Squibb (BMY)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
BioMarin Pharmaceutical (BMRN)
Avidity Biosciences Ord (RNA)
Agios Pharmaceuticals Call Option (AGIO)
Ultragenyx Pharmaceutical (RARE)
Incyte Corporation Call Option (INCY)
Intellia Therapeutics Call Option (NTLA)
Vaxcyte (PCVX)
Eli Lilly & Co. Put Option (LLY)

View all positions for Diadema Partners

Top funds holding Sellas Life Sciences Group I

Vanguard Group
Frigate Ventures
BlackRock
Susquehanna International
Marshall Wace
Caligan Partners
Geode Capital Management
State Street Corporation
Morgan Stanley
Nuveen
Citadel Advisors
Northern Trust
GSA Capital Partners
Diadema Partners
Everhart Financial Group

View all funds holding Sellas Life Sciences Group I